Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05673785 · FLOW

Participant flow

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) · Source last updated 2026-06-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received brentuximab vedotin 1.8 milligrams per kilogram (mg/kg), intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 milligrams per square meter (mg/m\^2) and doxorubicin 50 mg/m\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurred first.
    id
    FG000
    title
    Brentuximab Vedotin + CHP
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Lost to follow up
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        46
      type
      Ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        52
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        52
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 52 participants with newly diagnosed CD30-positive (CD30+) peripheral T-cell lymphomas (PTCL) were enrolled in the study and treated with brentuximab vedotin in combination with cyclophosphamide, doxorubicin (hydroxydaunorubicin) and prednisone (CHP). The results presented are until the primary completion date.
recruitment Details
Participants took part in the study at 14 investigative sites in China from 10 February 2023 to 27 April 2025. The study is ongoing.
Complete source fields
groups
  1. description
    Participants received brentuximab vedotin 1.8 milligrams per kilogram (mg/kg), intravenous (IV) infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 milligrams per square meter (mg/m\^2) and doxorubicin 50 mg/m\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until progressive disease (PD), unacceptable toxicity, whichever occurred first.
    id
    FG000
    title
    Brentuximab Vedotin + CHP
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Lost to follow up
    3. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        46
      type
      Ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        52
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        52
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 52 participants with newly diagnosed CD30-positive (CD30+) peripheral T-cell lymphomas (PTCL) were enrolled in the study and treated with brentuximab vedotin in combination with cyclophosphamide, doxorubicin (hydroxydaunorubicin) and prednisone (CHP). The results presented are until the primary completion date.
recruitment Details
Participants took part in the study at 14 investigative sites in China from 10 February 2023 to 27 April 2025. The study is ongoing.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice